Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 1, 2014
The Boston Scientific Lotus™ Valve System advanced TAVR technology continued to demonstrate impressive performance at three months, according to new data presented at ACC 2014. The REPRISE II...
-
Mar 30, 2014MADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE: BSX) exclusively sponsored and landmark...
-
Mar 30, 2014MADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE: BSX) exclusively sponsored and landmark...
-
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads. Pacing leads...
-
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads. Pacing leads...
-
Mar 13, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for Patients
Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's...
-
Mar 12, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for Patients
Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's...
-
Feb 25, 2014Dystonia Europe (DE) and The European Parkinson’s Disease Association (EPDA) announced today that they are collaborating with Boston Scientific Corporation (NYSE:BSX), a global medical technology leader. The aim of these partnerships is to increase awareness, understanding of solutions and to take initiatives in the worldwide fight against Parkinson’s disease and dystonia, two areas of high unmet need.
Both Parkinson’s and dystonia are neurological diseases which include involuntary body movements such as tremors, sustained muscle contractions and abnormal twisting or postures, often referred...
-
Feb 24, 2014Dystonia Europe (DE) and The European Parkinson’s Disease Association (EPDA) announced today that they are collaborating with Boston Scientific Corporation (NYSE:BSX), a global medical technology leader. The aim of these partnerships is to increase awareness, understanding of solutions and to take initiatives in the worldwide fight against Parkinson’s disease and dystonia, two areas of high unmet need.
Both Parkinson’s and dystonia are neurological diseases which include involuntary body movements such as tremors, sustained muscle contractions and abnormal twisting or postures, often referred...
-
Feb 24, 2014
Dystonia Europe (DE) and The European Parkinson’s Disease Association (EPDA) announced today that they are collaborating with Boston Scientific Corporation (NYSE:BSX), a global medical...
-
Feb 24, 2014
Dystonia Europe (DE) and The European Parkinson’s Disease Association (EPDA) announced today that they are collaborating with Boston Scientific Corporation (NYSE:BSX), a global medical...
-
Jan 10, 2014
Die Boston Scientific Corporation (NYSE:BSX) hat heute den Einschluss des ersten deutschen Patienten in das EWOLUTION-Register (REgistry on WATCHMAN Outcomes in Real-Life Utilization) bekannt...
-
Dec 17, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided highly significant pain...
-
Dec 6, 2013
New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain New retrospective...
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided highly significant pain...
-
Nov 15, 2013Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the Boston Scientific (NYSE: BSX) Lotus™ Valve...
-
Nov 15, 2013
Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment Marking a major step forward in the evolution of...
-
Nov 6, 2013Das Gerät zum Transkatheter-Aortenklappenersatz (TAVR) ermöglicht eine präzise Positionierung und Platzierung, die Ärzten eine bisher unerreichte Kontrolle bietet
Boston Scientific Corporation (NYSE: BSX) hat für das Lotus™-Klappensystem, der fortgeschrittenen Technologie zum Transkatheter-Aortenklappenersatz (TAVR), die CE-Kennzeichnung erhalten. Diese...
-
Nov 6, 2013Im Rahmen der TCT-Konferenz präsentierte Daten der REDUCE-HTN Studie belegen das exzellente Sicherheitsprofil
Bei Patienten, die mit dem Vessix™-System zur renalen Denervierung von Boston Scientific (NYSE: BSX) behandelt wurden, zeigte sich eine signifikante und nachhaltige Blutdrucksenkung. Dies...
-
Nov 1, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The completion of this...
-
Oct 30, 2013
Boston Scientific Corporation (NYSE:BSX) today announced the first German patient enrolment in the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization, a prospective multicentre...